Home » Stocks » Merck

Merck & Co., Inc. (MRK)

Stock Price: $85.81 USD 0.17 (0.20%)
Updated Sep 18, 2020 4:03 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 217.03B
Revenue (ttm) 47.19B
Net Income (ttm) 10.48B
Shares Out 2.53B
EPS (ttm) 4.10
PE Ratio 20.93
Forward PE 13.26
Dividend $2.44
Dividend Yield 2.84%

Stock Quote

Trading Day Sep 18, 2020
Last Price $85.81
Previous Close $85.64
Change ($) 0.17
Change (%) 0.20%
Day's Open 85.43
Day's Range 84.94 - 86.30
Day's Volume 11,770,139
52-Week Range 65.25 - 92.64

More Stats

Market Cap 217.03B
Enterprise Value 236.81B
Earnings Date (est) Oct 27, 2020
Ex-Dividend Date Sep 14, 2020
Shares Outstanding 2.53B
Float 2.53B
EPS (basic) 4.13
EPS (diluted) 4.10
FCF / Share 3.70
Dividend $2.44
Dividend Yield 2.84%
Earnings Yield 4.78%
FCF Yield 4.31%
Payout Ratio n/a
Shares Short 12.11M
Short Ratio 1.66
Short % of Float 0.48%
Beta 0.47
PE Ratio 20.93
Forward PE 13.26
P/FCF Ratio 23.23
PS Ratio 4.60
PB Ratio 7.83
Revenue 47.19B
Operating Income 11.99B
Net Income 10.48B
Free Cash Flow 9.34B
Net Cash -19.77B
Net Cash / Share -7.82
Gross Margin 71.37%
Operating Margin 25.40%
Profit Margin 22.20%
FCF Margin 19.80%
ROA 11.19%
ROE 37.85%
ROIC 26.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 12
Overweight 2
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$95.88*
(11.74% upside)
Low
84.0
Current: $85.81
High
107.0
Target: 95.88
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue46,84042,29440,12239,80739,49842,23744,03347,26748,04745,987
Revenue Growth10.75%5.41%0.79%0.78%-6.48%-4.08%-6.84%-1.62%4.48%-
Gross Profit32,72828,78527,21025,77724,56425,46927,07930,82131,17627,591
Operating Income11,6038,2996,0214,8486,9285,6705,9569,2137,6702,370
Net Income9,8436,2202,3943,9204,44211,9204,4046,1686,272861
Shares Outstanding2,5462,6002,7242,7572,7942,8512,9223,0403,0483,081
Earnings Per Share3.812.320.871.411.564.071.472.002.020.28
EPS Growth64.22%166.67%-38.3%-9.62%-61.67%176.87%-26.5%-0.99%621.43%-
Dividend Per Share2.261.991.891.851.811.771.731.691.561.52
Dividend Growth13.57%5.29%2.16%2.21%2.26%2.31%2.37%8.33%2.63%-
Operating Cash Flow13,44010,9226,45110,37612,5387,98911,65410,02212,38310,822
Capital Expenditures-3,473-2,615-1,888-1,614-1,283-1,317-1,548-1,954-1,723-1,678
Free Cash Flow9,9678,3074,5638,76211,2556,67210,1068,06810,6609,144
Cash & Equivalents10,4508,8648,49814,34113,42715,71917,48616,14114,97212,201
Total Debt26,34625,11424,41024,84226,41221,40325,06020,56917,51517,882
Net Cash / Debt-15,896-16,250-15,912-10,501-12,985-5,684-7,574-4,428-2,543-5,681
Assets84,39782,63787,87295,377101,67798,167105,645106,132105,128105,781
Liabilities58,39655,75553,30355,06956,91049,37653,31950,66948,18548,976
Book Value25,90726,70134,33640,08844,67648,64749,76553,02054,51754,376
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merck & Co., Inc.
Country United States
Employees 71,000
CEO Kenneth C. Frazier

Stock Information

Ticker Symbol MRK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: MRK

Description

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; and FUJIFILM Corporation. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Address: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033